ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 202

Diseases Associated with Markedly Elevated Ferritin Levels

Reshma Marri1, Payal J. Patel2, Amita Thakkar3, Rochella A. Ostrowski4, Eric McBride1 and Rodney Tehrani5, 1Rheumatology, Loyola Univ Medical Ctr, Maywood, IL, 2Internal Medicine, Loyola Univ Medical Ctr, Maywood, IL, 3Loyola Univ Medical Ctr, Maywood, IL, 4Rheumatology, Loyola University Medical Center, Maywood, IL, 5Allergy, Immunology, and Rheumatology, Loyola University Medical Center, Maywood, IL

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Adult-onset Still's disease and malignancy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Miscellaneous Rheumatic and Inflammatory Diseases: Periodic Fever Syndromes

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Adult onset Still’s disease (AOSD) is a rare form of inflammatory arthritis with inflammatory systemic disease of unknown etiology.  It is a diagnosis of exclusion and can be a diagnostic challenge.  A patient with suspected AOSD at our institution prompted a retrospective chart review of all patients with markedly elevated ferritin levels.  

The patient, a 59 year old male with fever of at least one month who underwent an extensive negative evaluation for infection, malignancy, and other autoimmune etiologies was treated with high dose corticosteroids.  A ferritin level at admission was 2200 ng/mL and rapidly rose to almost 50,000 ng/mL.  Treatment for AOSD with IL-1 and IL-6 inhibition was unsuccessful and he died within one month from multi-organ failure.  A bladder wall biopsy obtained just prior to death revealed an anaplastic large cell lymphoma.

Methods:

In order to determine the association of autoimmune disease, including AOSD, with markedly elevated ferritin levels, in comparison to non-autoimmune diagnoses, we conducted a retrospective chart review of patients with elevated ferritins > 10,000 ng/mL seen at our institution from January 2000 to July 2011.  Cases were divided into two subgroups, those with values between 10,000-15,000 and >15,000 ng/ml for analysis. The highest ferritin value was used when an individual subject had multiple values. There were 108 charts identified and reviewed for diagnoses at the time of the elevated ferritin level. Patients with either autoimmune disease, malignancies, liver disease, and/or infection were included in the analysis. Patients with hemoglobinopathies were excluded to avoid confounding of the ferritin levels by frequent blood transfusions. The remaining 88 cases were included for analysis. 

Results:

Twenty six patients with ferritin levels between 10,000-15,000 ng/ml were identified. The mean age of patients in this subgroup was 46.6 years.  Of these patients, 10/26 (38%) had elevated ferritin levels secondary to liver disease, 7/26 (27%) malignancy/infection, 6/26 (23%) malignancy alone, 1/26 (4%) autoimmune disease, and 1/26 (4%) infection and liver disease/infection respectively.   There were 62 patients with ferritins greater than 15,000 with a mean age of 44.3 years.  Of these patients, 29/62 (47%) had liver disease, 9/62 (14%) malignancy, 7/62 (11%) autoimmune, 7/62 (11%) infection, 4/62 (6%) liver disease/infection, 4/62 (6%) malignancy/infection and 2/62 (3%) autoimmune/infection.

Conclusion:

The observation that both ferritin groups include higher percentages of patients with liver disease and malignancy compared to autoimmune disease.  Although not a part of the diagnostic criteria for AOSD, the presence of hyperferritinemia is commonly used to assist with diagnosis.  These findings suggest that other diagnoses such as malignancies or liver disease should be considered in the differential diagnoses of markedly elevated ferritin levels.  The diagnosis of AOSD is a diagnosis of exclusion and other underlying causes need to be ruled out.


Disclosure:

R. Marri,
None;

P. J. Patel,
None;

A. Thakkar,
None;

R. A. Ostrowski,
None;

E. McBride,
None;

R. Tehrani,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/diseases-associated-with-markedly-elevated-ferritin-levels/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology